Unilife CEO Alan Shortall Announces EZmix Syringes and Correlating Future Growth
Unilife CEO Alan Shortall recently offered new information about the development and patenting of Unilife's Unifill® EZMix multiple-chamber ready-to-fill (prefilled) syringes.
- York-Hanover, PA (1888PressRelease) August 28, 2011 - Unilife is a U.S.-based developer, manufacturer and supplier of advanced drug delivery systems, with Unilife CEO Alan Shortall leading the expansion of business into new areas of production.
The CEO of Unilife Alan Shortall reported, "The Unifill EZMix syringes are being developed as a direct response to the pharmaceutical market's need for a convenient delivery system for the reconstitution and administration of lyophilized drugs and vaccines." Unilife CEO Alan Shortall also stated that the lyophilization technology applications in the pharmaceutical industry will enhance the stability or shelf life of different drug formulations like vaccines and other injectable drugs. Unilife CEO Alan Shortall has driven the company's global expansion over the last twenty-four months.
According to Unilife CEO Alan Shortall, Unifill EZMix features include:
• Two or more primary drug containers within a single glass barrel to store a combination of liquid stable or lyophilized drugs along with up to 1mL of dilutent for reconstitution.
• The world's first and only dual or multi-chamber prefilled syringes with automatic (passive) safety features fully integrated within the glass barrel.
• Available with either a fixed (staked) needle for drugs indicated for subcutaneous injections, or with attachable needles of up to 1.5 inches in length.
Unilife's Alan Shortall also explained that the Unifill EZMix delivers a product that requires minimal steps of use for both healthcare workers and patients. Shortall described the process: "The end-user simply advances the plunger to mix the lyophilized powder with the dilutent, before swirling the device to complete reconstitution. An audible, tactile 'click' signals the injection of the full dose and the activation of a passive safety system that allows operators to control the speed of needle retraction directly from the body into the barrel, said Unilife CEO Alan Shortall.
"Unifill EZMix syringes are designed to address the unmet needs of pharmaceutical and biotechnology companies active within the large, fast-growing market for lyophilized drugs and vaccines," CEO of Unilife Alan Shortall stated. "Nearly a third of all novel drugs approved by the FDA in the last three years were lyophilized either because a drug's large molecular composition made it unsuitable for liquid stable form or a pharmaceutical company wanted to fast-track the time to market" through Unilife. Alan Shortall also noted that "with the development pipelines of many pharmaceutical companies teeming with complex biologics that must be reconstituted at the point of delivery" he anticipated the market to experience "double-digit growth."
The CEO of Unilife, Alan Shortall, also pointed out that, "Pharmaceutical companies recognize that innovative, convenient devices can help enhance therapy compliance, improve patient care and generate powerful brand differentiation within competitive therapeutic classes, therefore enabling them to increase market share and revenue." Unilife CEO Alan Shortall added that, until now, a fully integrated delivery system that combines convenient drug reconstitution, intuitive use by the operator and optimal protection from needle stick injuries has not been available. According to Unilife CEO Alan Shortall, the "Unifill EZMix syringes bring these distinct market needs together in one elegant and highly effective drug delivery system."
This latest announcement comes on the heels of a number of progressive moves made by Unilife CEO Alan Shortall and his Pennsylvania based team. While most people are not aware of the Federal Needle stick Prevention Act passed in 2000, Unilife CEO Alan Shortall is positioned directly in the middle of a major paradigm shift within the pharmaceutical industry. The market is clearly ready for the fully integrated safety syringes offered by Unilife. Alan Shortall has moved quickly through the approval process and has expanded the company's manufacturing capacity as well.
The global market opportunity for prefilled syringes includes 50 drugs that are delivered by injection, including an estimated 3 billion prefilled syringes in use by 2012, according to CEO of Unilife Alan Shortall. There is a distinct advantage with a disruptive technology like this since there are currently no prefilled syringes to deliver medications with fully-integrated safety features such as offered by Unilife. Alan Shortall stated that the company is strategically positioned to rapidly expand, and that this is what the Board of Unilife and Alan Shortall are anticipating.
Unilife Corporation is a U.S. based developer and manufacturer of a diversified portfolio of advanced drug delivery systems. Since CEO and Executive Director Alan Shortall founded Unilife in 2002, he has been a principal driving force behind the company's rapid global expansion. At Unilife, Alan Shortall has led the Company in the development, patent-protection and diversification of its broad device portfolio, which includes a best-in-class technology platform of safety syringes. As the leader of Unilife, Alan Shortall has also attracted world-class experts from the pharmaceutical and medical device industries to the Board and executive management team.
Between 2008 and 2010, Alan Shortall spearheaded Unilife's transition from Australia to a fully based and registered U.S. business. This included the redomiciliation of Unilife by Alan Shortall and associates into a Delaware registered Company, and its listing on the NASDAQ stock exchange (NASDAQ:UNIS) in February 2010. Unilife also continues to trade on the Australian Stock Exchange (UNS:ASX).
For more information about Alan Shortall, Unilife, or the Unifill prefill syringe, visit the company online at http://unilife.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam